These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 15360094

  • 1. Treatment of acute bacterial rhinosinusitis caused by antimicrobial-resistant Streptococcus pneumoniae.
    Anon JB.
    Am J Med; 2004 Aug 02; 117 Suppl 3A():23S-28S. PubMed ID: 15360094
    [Abstract] [Full Text] [Related]

  • 2. Efficacy/safety of amoxicillin/clavulanate in adults with bacterial rhinosinusitis.
    Anon JB, Berkowitz E, Breton J, Twynholm M.
    Am J Otolaryngol; 2006 Aug 02; 27(4):248-54. PubMed ID: 16798401
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB, Ferguson B, Twynholm M, Wynne B, Berkowitz E, Poole MD.
    Ear Nose Throat J; 2006 Aug 02; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [Abstract] [Full Text] [Related]

  • 4. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children.
    Hoberman A, Dagan R, Leibovitz E, Rosenblut A, Johnson CE, Huff A, Bandekar R, Wynne B.
    Pediatr Infect Dis J; 2005 Jun 02; 24(6):525-32. PubMed ID: 15933563
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb 02; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 6. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.
    File TM, Benninger MS, Jacobs MR.
    Clin Lab Med; 2004 Jun 02; 24(2):531-51. PubMed ID: 15177852
    [Abstract] [Full Text] [Related]

  • 7. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J.
    Clin Microbiol Infect; 2004 Apr 02; 10 Suppl 2():28-35. PubMed ID: 14759231
    [Abstract] [Full Text] [Related]

  • 8. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V, Hoover J, Singley C, Woodnutt G.
    Antimicrob Agents Chemother; 2005 Mar 02; 49(3):908-15. PubMed ID: 15728883
    [Abstract] [Full Text] [Related]

  • 9. Acute bacterial rhinosinusitis: clinical impact of resistance and susceptibility.
    Poole MD.
    Am J Med; 2004 Aug 02; 117 Suppl 3A():29S-38S. PubMed ID: 15360095
    [Abstract] [Full Text] [Related]

  • 10. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.
    Benninger MS.
    Expert Opin Pharmacother; 2003 Oct 02; 4(10):1839-46. PubMed ID: 14521493
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of coamoxiclav and other antibiotics against S pneumoniae and H influenae from paediatric cases of acute respiratory infections.
    Krishnan P, Rajendran P, Sambandan AP, Anitha C, Chavda RK, Khobragade KJ.
    J Indian Med Assoc; 2011 Apr 02; 109(4):241-2, 244. PubMed ID: 22187795
    [Abstract] [Full Text] [Related]

  • 12. Acute bacterial rhinosinusitis in pediatric medicine: current issues in diagnosis and management.
    Anon JB.
    Paediatr Drugs; 2003 Apr 02; 5 Suppl 1():25-33. PubMed ID: 14632103
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov 02; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 14. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM, Prause JL, Danziger LH, Pendland SL.
    Antimicrob Agents Chemother; 2001 Dec 02; 45(12):3613-5. PubMed ID: 11709352
    [Abstract] [Full Text] [Related]

  • 15. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan 02; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 16. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
    MacGowan AP, Noel AR, Rogers CA, Bowker KE.
    Antimicrob Agents Chemother; 2004 Jul 02; 48(7):2599-603. PubMed ID: 15215115
    [Abstract] [Full Text] [Related]

  • 17. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
    File TM, Jacobs MR, Poole MD, Wynne B, 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups.
    Int J Antimicrob Agents; 2002 Oct 02; 20(4):235-47. PubMed ID: 12385678
    [Abstract] [Full Text] [Related]

  • 18. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V, Thorburn CE, Knott SJ, Woodnutt G.
    Antimicrob Agents Chemother; 1998 Dec 02; 42(12):3193-9. PubMed ID: 9835514
    [Abstract] [Full Text] [Related]

  • 19. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A, Aguilar L, Robledo O, Giménez MJ, Tarragó D, Granizo JJ, Gimeno M, Coronel P.
    J Antimicrob Chemother; 2007 Aug 02; 60(2):323-7. PubMed ID: 17562681
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group.
    Int J Antimicrob Agents; 2002 Aug 02; 20(2):119-29. PubMed ID: 12297361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.